No Data Yet
Co-Diagnostics (CODX) shares fell 21.1% after the company announced it received an Australian patent for its new Co-Dx PCR platform.
Co-Diagnostics (CODX) announced its joint venture is advancing key diagnostic tests to clinical trials in India, yet its stock price fell 4.35%.